72% of patients achieved a positive response to treatment in a study involving 100 patients conducted at the Mayo Clinic, Rochester, Minnesota, USA.
40 of the patients had been receiving steroid treatment and nearly 75% were able to discontinue it.
Doctors reported that clinical responses lasted for 10 weeks.
|72% of patients experienced positive results following infliximab treatment.
|American Journal of Gastroenterology|
26 patients had fistulizing disease, and 65% of these showed benefits from treatment.
Mayo gastroenterologist Dr William Sandborn said, "Many of these patients have now received several infusions, and have done quite well for up to two years.
"These results are encouraging, because they confirm in clinical practice the promise that infliximab has offered to some very sick people for whom we have had no other good options.
"The experience in actual clinical practice when a drug becomes available for wider use can be disappointing.
"Our study was aimed at evaluating the real-world response to infliximab in a larger group of patients, including those with severe symptoms, and following them for at least three months to determine longer term benefit."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com